PMID-18046908 – Sermorelin Better Approach to Adult GH Insufficiency
Walker RF. Sermorelin: a better approach to management of adult-onset growth hormone insufficiency? Clin Interv Aging. 2006;1(4):307-308.
Quick Reference
| Property | Value |
|---|---|
| PMID | 18046908 |
| Year | 2006 |
| Journal | Clinical Interventions in Aging |
| Study Type | Narrative Review |
| Evidence Level | V |
| Sample | N/A (editorial/review) |
| Peptide(s) Studied | Sermorelin |
Key Findings
- Sermorelin stimulates endogenous GH production, preserving the natural pulsatile rhythm
- Unlike exogenous GH, sermorelin does not suppress the hypothalamic-pituitary feedback loop
- Sermorelin has a more favorable safety profile than recombinant GH for age-related GH decline
- The risk of GH excess (acromegalic features, insulin resistance) is inherently lower with GHRH stimulation
- Sermorelin may be preferable to GH for "somatopause" management due to self-limiting GH release
- The physiological feedback mechanism prevents dangerous GH elevations
- Cost may be more favorable compared to recombinant GH therapy
Study Design
Expert review/editorial discussing the clinical rationale for using sermorelin (GHRH analog) rather than exogenous GH for age-related GH insufficiency. Compares safety and efficacy profiles.
Limitations
- Brief editorial format; not a systematic review
- Published in 2006; does not reflect modern peptide therapy landscape
- Does not address the subsequent withdrawal of sermorelin (Geref) from market
Clinical Relevance
Articulates the key clinical advantage of GHRH analogs over exogenous GH: the preservation of physiological feedback control. This "safety net" against GH excess is the primary argument for sermorelin in anti-aging medicine. The self-limiting nature of GHRH-stimulated GH release is why peptide therapy practitioners prefer secretagogues over direct GH replacement.
Related
#research #narrative-review #sermorelin #evidence-level-V